Simultaneously, elevated JNK2 expression leads to increased β-catenin nuclear translocation, where it acts as a transcription factor, promoting the expression of EMT genes and facilitating the EMT and metastasis of prostate cancer cells. The gene discussed is MAPK9; the disease is prostate carcinoma.